Overview
CORT market data
Price History
CORT price chart
Valuation & Profitability
- P/E (TTM)
- 217.77 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.83 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.48 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $28.66 – $97.05 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $10.3K · P/B 11.40 · P/S 13.41.
Company news
8-K filing — CORCEPT THERAPEUTICS INC (CORT)SEC EDGAR · Jun 17, 2026, 8:36 PM
Corcept Therapeutics Refiles Its New Drug Application With Additional Analyses Of Data To FDA For Relacorilant To Treat Cushing's SyndromeBenzinga · Jun 17, 2026, 8:35 PM
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?The Motley Fool · Jun 4, 2026, 6:15 PM
Corcept Therapeutics Announces New Overall Survival Data From Its Pivotal Phase 3 ROSELLA Trial Of Lifyorli Plus Nab-Paclitaxel In An Oral Presentation At The ASCO 2026; Patients Treated With Lifyorli Combined With Nab-Paclitaxel Experienced A 35 Percent Reduction In The Risk Of Death Compared To Patients Treated With Nab-paclitaxel AloneBenzinga · May 29, 2026, 8:40 PM
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $135Benzinga · May 28, 2026, 6:08 PM
Micron To Rally Around 24%? Here Are 10 Top Analyst Forecasts For ThursdayBenzinga · May 28, 2026, 12:00 PM
HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $95Benzinga · May 28, 2026, 11:00 AM
Corcept Therapeutics shares are trading higher after the company announced it will resubmit its New Drug Application to the FDA.Benzinga · May 27, 2026, 12:57 PM
Corcept Therapeutics To Resubmit Its New Drug Application To FDA For Relacorilant To Treat Cushing's Syndrome PatientsBenzinga · May 27, 2026, 12:01 PM
Corcept Therapeutics shares are trading higher after UBS upgraded the stock from Neutral to Buy and raised its price target from $44 to $72.Benzinga · May 13, 2026, 3:20 PM